SEARCH RESULTS
Your search for "" returned the following 531 results.
BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 Mutations
- Global trial designed to study the safety, tolerability and efficacy of bemcentinib in combination with current standard of care – BERGEN, Norway, March 9, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced the first patient was dosed in a Phase 1b/2a trial evaluating bemcentinib…
Read MoreQ4 2022 Report
Read MoreBerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update
BERGEN, Norway, February 16, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the fourth quarter ended December 31, 2022, and provided a business update. A briefing by BerGenBio's senior management team will take place at 10:00 am CET today via a webcast…
Read MoreBerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients
- The Company will discuss the topline results during its Q4 2022 results presentation on Thursday, February 16, 2023, at 10:00 AM CET - BERGEN, Norway, February 15, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced topline data from BGBC008, a phase 2 trial evaluating…
Read MoreScientific Advisory Board
BerGenBio is proud to have the involvement of a scientific advisory board consisting of world-renowned non-small cell lung cancer (NSCLC) experts from top oncology centers around the globe.
Read More
